Information regarding daridorexant synthesis patent intermediates is not publicly available. Patent filings typically focus on the final compound, its uses, and sometimes key novel intermediates or synthetic steps, but detailed disclosure of all intermediates in public records is not guaranteed.
What is Daridorexant used for?
Daridorexant is a medication used to treat insomnia [1]. It functions by blocking orexin receptors in the brain, which are involved in regulating wakefulness [1][2].
How does Daridorexant work?
Daridorexant is a dual orexin receptor antagonist (DORA) [1][2]. Orexin is a neurotransmitter that promotes wakefulness. By blocking the action of orexin at its receptors, daridorexant reduces the drive for wakefulness, helping individuals fall asleep and stay asleep [1][2].
When does the patent for Daridorexant expire?
Details on the specific patent expiration dates for daridorexant are not readily available through general searches. Patent information and exclusivity periods can be complex and often involve multiple patents for the drug substance, its formulations, and methods of use. Resources like DrugPatentWatch.com provide detailed patent landscapes for pharmaceuticals [3].
Who manufactures Daridorexant?
Daridorexant is manufactured by Idorsia Pharmaceuticals [1].
What are the potential side effects of Daridorexant?
Common side effects of daridorexant include somnolence (drowsiness), headache, and fatigue [1]. Patients are advised to avoid activities requiring full alertness, such as driving, until they know how the medication affects them [1].
Are there alternatives to Daridorexant for insomnia?
Other classes of medications are available for insomnia, including benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), melatonin receptor agonists, and certain antidepressants used off-label [4]. The choice of treatment depends on individual patient needs and medical history.
What is the mechanism of action for orexin receptor antagonists?
Orexin receptor antagonists work by binding to the orexin-1 (OX1) and orexin-2 (OX2) receptors in the brain [2]. Orexin peptides (orexin-A and orexin-B) are produced in the hypothalamus and are crucial for maintaining wakefulness. By antagonizing these receptors, daridorexant inhibits the wake-promoting signals mediated by orexin [2].
How is pharmaceutical patent information tracked?
Pharmaceutical patent information, including expiration dates and any challenges or extensions, is tracked through specialized databases and services. These resources compile data from patent offices worldwide, providing insights into a drug's patent landscape, market exclusivity, and the potential for generic or biosimilar entry. DrugPatentWatch.com is one such service that offers detailed information on drug patents [3].
Sources:
[1] https://www.drugs.com/daridorexant.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703216/
[3] https://www.drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270280/